HomeIndustry NewsPharmaceuticalRoche in $2.3bn Deal for Hanmi Non-GLP-1 Obesity Drug
Roche in $2.3bn Deal for Hanmi Non-GLP-1 Obesity Drug
25th August 2026
Roche has signed a licensing deal worth up to $2.3 billion with South Korea’s Hanmi Pharm for HM17321, a clinical-stage UCN2 (urocortin-2) analogue being developed as a non-GLP-1 weight loss therapy. Announced on 24 August 2026, the deal marks Roche’s joint-largest transaction of the year and signals significant diversification of the Swiss pharma’s rapidly maturing obesity pipeline as it targets entry into the fast-growing global weight loss market
Under the licensing agreement, Roche is paying Hanmi $190 million upfront, with development, regulatory and commercial milestone payments taking the potential total to $2.3 billion. Roche’s Genentech will handle development, manufacturing and commercialisation, with Hanmi completing an ongoing Phase I trial (NCT07219589) evaluating HM17321 in healthy volunteers and individuals with obesity before Genentech takes over from Phase II. UCN2 is a neuropeptide that binds the corticotropin-releasing hormone receptor 2 (CRHR2) and reduces rates of muscle atrophy, positioning HM17321 as differentiated against GLP-1 and GIP-based therapies criticised for muscle mass loss during weight reduction.
Preclinical studies showed HM17321 delivered improvements in weight reduction as both monotherapy and in combination with GLP-1 therapies, with potential future application in fixed-dose combination or incretin-based regimens. The deal extends Roche’s obesity portfolio, joining lead candidate CT-388 (acquired via the $2.7 billion Carmot Therapeutics deal in 2023) and emugrobart, an anti-myostatin antibody. GlobalData projects the obesity market growing at 32.3% CAGR to $173.5 billion across seven major markets by 2031, while Eli Lilly’s Q2 2026 revenue reached $23 billion (up 48% year-on-year) buoyed by injectable weight loss drug growth.
The commercial signal is a global obesity therapeutics category consolidating around differentiated mechanisms as GLP-1 dominance faces increasing scientific and reimbursement pressure over muscle mass concerns. Roche’s non-GLP-1 diversification strategy through Hanmi’s UCN2 analogue represents a strategic hedge. Expect Novo Nordisk, Eli Lilly, Pfizer (Metsera), Amgen and other major obesity players to accelerate their non-GLP-1 mechanism strategies through 2027 and 2028
For the latest updates and in-depth insights into the world of Pharmaceuticals, including breakthrough treatments, industry trends, and regulatory news, contact Katie Ginger today!
We have hundreds of jobs available across the Healthcare industry, find your perfect one now
Search all jobs
Stay informed
Receive the latest industry news, Tips and straight to your inbox
Related Articles
J&J’s Imaavy Wins FDA Nod for Rare Blood Disorder wAIHA
Read Article
Andelyn to Manufacture Queen’s AAV9-GM2 Gene Therapy
Read Article
